Iterative Health

Executive Summary

Iterative Health leverages AI and machine learning to transform clinical trial execution in gastroenterology and hepatology. By operating a global, performance-driven network of community-embedded research sites, the company addresses critical bottlenecks in patient enrollment, site selection, and operational efficiency. Its model connects biopharma sponsors and CROs with high-performing sites, reducing trial timelines and costs. With a focus on a high-unmet-need therapeutic area, Iterative Health is positioned to accelerate the delivery of novel therapies to market, benefiting from the growing demand for decentralized and AI-enhanced trial solutions.

Upcoming Catalysts (preview)

• Q3 2026Strategic partnership with a top-10 pharma company for GI trial network access60% success
• Q4 2026Series B funding round led by healthcare-focused venture capital70% success
• Q2 2027First primary completion of a pivotal trial using AI-enabled site selection50% success